Of the disease-modifying trials currently in the AD pipeline, 52 use amyloid imaging and/or CSF to support the diagnosis, 20 have amyloid imaging as an outcome, ten have tau imaging as an outcome of the intervention. The gene discussed is MAPT; the disease is Alzheimer disease.